March 28, 2019
Chuikyo Joint CEA Subcommittee Meeting on March 27 Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) will go through yet another re-pricing after regulators performed confirmatory analyses on the results of its pilot cost-effectiveness assessment (CEA) program. However, its new NHI price...read more